Juno Therapeutics, Inc. (NASDAQ:JUNO) Files An 8-K Regulation FD Disclosure

Juno Therapeutics, Inc. (NASDAQ:JUNO) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01

Regulation FD Disclosure.
On January 9, 2017, Juno Therapeutics, Inc. (Juno)>released an
updated corporate presentation, a copy of which is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 7.01 of this Form 8-K (including Exhibit
99.1) shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference under the Securities Act of 1933, as
amended, except as expressly set forth by specific reference in
such a filing, regardless of any general incorporation language
in any such filing, unless Juno expressly sets forth in such
filing that such information is to be considered filed or
incorporated by reference therein.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Juno Therapeutics, Inc. Corporate Presentation –
January 2017

About Juno Therapeutics, Inc. (NASDAQ:JUNO)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

Juno Therapeutics, Inc. (NASDAQ:JUNO) Recent Trading Information

Juno Therapeutics, Inc. (NASDAQ:JUNO) closed its last trading session up +0.16 at 20.34 with 1,135,622 shares trading hands.

An ad to help with our costs